Neuroprotection induced by dexpramipexole delays disease progression in a mouse model of progressive multiple sclerosis

Abstract

The present findings corroborate the hypothesis that neuroprotective agents may be of relevance to counteract MS progression and disclose the translational potential of dexpramipexole to treatment of progressive MS patients as a stand-alone or adjunctive therapy.